Aurora medical patients now have expanded
access to company's full portfolio of adult-use cannabis
brands
EDMONTON, AB, Oct. 17,
2022 /PRNewswire/ - Aurora Cannabis (NASDAQ: ACB)
(TSX: ACB), the Canadian company defining the future of
cannabinoids worldwide, today announced a new and unprecedented
fall lineup of cannabis products. New flower products include three
unique and proprietary strains from Aurora's esteemed breeding
program: Electric Honeydew, Ultra Grape Kush and
Organic BC White Grape OG.
"We are proud to introduce a significant number of innovative
and exciting products this fall, which were developed from a deep
understanding of consumer and patient interests and needs," says
Lana Culley, Vice President of
Product Development at Aurora Cannabis. "This extensive line up of
flower innovation was made possible from Aurora's differentiated
consumer preference mapping, which uniquely plots evolving cannabis
preferences, and the leading work of R&D to develop a portfolio
of products with the critical components necessary to compete –
intense and exciting aromas, key visual and tactile attributes, and
high-potency THC."
Aurora's best-in-class genetics breeding program, backed by
extensive consumer research and development, was the catalyst for
the company's most robust product release in over two years. Aurora
continues to focus on expanding its premium product offerings,
while developing unique cultivars and formats that appeal to a wide
variety of consumer and patient tastes. In the last 16 months,
Aurora has commercialized 12 original cultivars under its various
consumer brands.
New products launching this fall include:
Drift:
- Glitches – A first-of-its-kind high-potency chewable extract,
delivering 10mg THC per piece. Available in two flavours:
Pomegranate Berry (10 x 10mg) and Pineapple Coconut (5 x
10mg).
- Ultra Grape Kush (3.5g flower) – A mix of MK Ultra and Elite
Kush genetics, this proprietary indica cultivar delivers 20-26% THC
and incredible grape and gas aromas.
San Rafael '71:
- Electric Honeydew (3.5g flower) – A cross of Girl Scout Cookies
and 91 Krypt Melon, Electric Honeydew is a proprietary hybrid
cultivar with 24-30% THC, named for its nasal-tingling 'electric'
gas, pine and melon aroma.
- Buttered Toast (3.5g flower) - This sativa cultivar is named
for its high potency, densely frosted buds. A true sativa cultivar,
Buttered Toast has 23-29% THC and a doughy, creamy flavour
profile.
- Driftwood Diesel Shortcuts (3 x 0.35g infused pre-rolls) – A
new format for this popular cultivar, a mix of GMO and Fuel,
Driftwood Diesel Shortcuts are infused with milled live resin
derived 'dirty diamonds' for added potency and flavour. Delivered
in a reusable metal tin, these pre-rolls pack a punch with 27-32%
THC, and were developed to ensure no clogging or extinguishing
halfway through!
- Live Resin Sour Mix Pack Gummies (4 x 2.5mg) – Made with Pink
Kush live resin extracted from fresh-frozen cannabis using Aurora's
state-of-the-art hydrocarbon extraction process. These indica
gummies come in two flavours: Sour Peach and Sour Cherry.
- Sourdough (3 x 0.5g pre-rolls) – A cross of Wedding Cake and
Sour Diesel, Sourdough is an indica cultivar with 23-29% THC,
delivering bready notes combined with sour for a truly unique aroma
experience.
- Farm Gas (3 x 0.5g pre-rolls) – A mix of GMO and Sour Diesel,
Farm Gas is an indica cultivar with 22-28% THC and genuine gas and
savoury garlic flavours.
Whistler Cannabis Co.:
- Organic BC White Grape OG (3.5g flower) – A cross between Lemon
OG and The White, this proprietary cultivar is grown in living soil
with a small-batch approach. Delivering 24-30% THC and 4% terps,
this strain yields complex aromas including sour grape, tropical
fruit and diesel.
Daily Special:
- Spicy Mango Chili Soft Chews (2 x 5mg) – Infused with
high-quality CO2 resin derived from our most popular strains and
evenly dosed for a consistent and reliable experience.
- Pink Pepper OG – This spicy and floral indica cultivar delivers
20-26% THC and a pepper and spice flavour profile with notes of
lavender and lemon. Available in 3.5g and 15g flower, pre-rolls (7
x 0.5g) and vapes (510 – 1g).
- Nightmare Fuel – Derived from GMO and Fuel, Nightmare Fuel is
an indica cultivar with 22-28% THC, which gives off a strong and
distinct aroma of gas and chem, with earthy, nutty and musky notes.
Available in 3.5g and 15g flower, pre-rolls (7 x 0.5g), and vapes
(510 – 1g).
Starting this month, Aurora patients will have access to the
largest-ever selection of products and formats on Aurora Medical.
Alongside more than 60 new products on the channel will be Aurora's
full portfolio of adult-use cannabis brands, including Being
Quickstrips, Greybeard premium flower, a wider selection of
pre-rolls, new concentrates such as hash and live resin diamonds
and sauce, and a new offering of minor cannabinoid (CBN) oils.
The fall product release is set to roll out to patients on
Aurora Medical starting in October, followed by availability in
Canadian adult-use retailers, with select products available in
certain regions.
About Aurora:
Aurora is a global leader in the cannabis industry, serving both
the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Aurora Drift, San
Rafael '71, Daily Special, Whistler, Being and Greybeard, as well
as CBD brands, Reliva and KG7. Medical cannabis brands include
MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co.
Aurora also has a controlling interest in Bevo Farms, North America's leading supplier of propagated
agricultural plants. Driven by science and innovation, and with a
focus on high-quality cannabis products, Aurora's brands continue
to break through as industry leaders in the medical, performance,
wellness and adult recreational markets wherever they are launched.
Learn more at www.auroramj.com and follow us on Twitter and
LinkedIn. Aurora's common shares trade on the NASDAQ and TSX
under the symbol "ACB".
Forward-looking
Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include, but are not limited to, statements with respect to
product innovation and new products to market, competitive
advantages including breeding and genetics and consumer research,
and the expected timing for the release of new products in the
medical and recreational channels.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news
release have been developed based on assumptions
management considers to be reasonable. Material factors
or assumptions involved in developing forward-looking statements
include, without limitation, publicly available information from
governmental sources as well as from market research and industry
analysis and on assumptions based on data and knowledge of this
industry which the Company believes to be reasonable.
Forward-looking statements are subject to a variety of risks,
uncertainties and other factors that management believes to be
relevant and reasonable in the circumstances could cause actual
events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks
include, but are not limited to, the ability to retain key
personnel, the ability to continue investing in infrastructure to
support growth, the ability to obtain financing on acceptable
terms, the continued quality of our products, customer experience
and retention, the development of third party government and
non-government consumer sales channels, management's
estimates of consumer demand in Canada and in jurisdictions where the Company
exports, expectations of future results and expenses, the risk
of successful integration of acquired business and operations,
management's estimation that SG&A will grow only in proportion
of revenue growth, the ability to expand and maintain distribution
capabilities, the impact of competition, the general impact of
financial market conditions, the yield from cannabis growing
operations, product demand, changes in prices of required
commodities, competition, and the possibility for changes in laws,
rules, and regulations in the industry, epidemics, pandemics or
other public health crises, including the current outbreak of
COVID-19, and other risks, uncertainties and factors set out under
the heading "Risk Factors" in the Company's annual information form
dated September 20, 2022 (the "AIF")
and filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR at www.sedar.com and
filed with and available on the SEC's website
at www.sec.gov. The Company cautions that the list
of risks, uncertainties and other factors described in the AIF is
not exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking statements
and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-announces-unprecedented-fall-product-release-across-adult-use-and-medical-markets-301650283.html
SOURCE Aurora Cannabis Inc.